Market revenue in 2023 | USD 292.2 million |
Market revenue in 2030 | USD 1,802.6 million |
Growth rate | 29.7% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.19% in 2023. Horizon Databook has segmented the India cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
India is expected to emerge as one of the lucrative markets for pharmaceutical CDMOs across the globe. This can be attributed to low costs, the availability of industry experts, and the presence of WHOcGMP-compliant facilities.
In addition, some of the key players in India providing CDMO services are Wuxi AppTec; Charles River Laboratories International, Inc.; IQVIA; Recipharm AB; and Catalent, Inc. Local players include Dr. Reddy’s Laboratories, Cadila Healthcare Limited, and Cipla Ltd. Several CMOs & CROs operating in India have expanded their facilities to meet the growing demand for pharmaceuticals.
Moreover, leading players are actively seeking to expand their customer base, production capacities, and market presence. For instance, in October 2023, a new formulations manufacturing facility was commissioned by Aragen, a leading provider of contract research, development, and manufacturing services for pharmaceutical & biotechnology industries, in Hyderabad, India.
Horizon Databook provides a detailed overview of country-level data and insights on the India cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into India cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account